{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:34:44Z","timestamp":1791304484230,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 113-S0284"],"award-info":[{"award-number":["NTUH 113-S0284"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejca.2025.115224","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T11:31:16Z","timestamp":1736249476000},"page":"115224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study"],"prefix":"10.1016","volume":"217","author":[{"given":"Hsin-Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8889-689X","authenticated-orcid":false,"given":"Shang-Gin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-0733","authenticated-orcid":false,"given":"Chia-Lin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-9140","authenticated-orcid":false,"given":"Yen-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2025.115224_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non\u2013small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115224_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejca.2022.05.012","article-title":"Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients","volume":"171","author":"Cui","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115224_bib3","article-title":"Comprehensive genomic analysis of patients with non\u2013small-cell lung cancer using blood-based circulating tumor DNA assay: findings from the BFAST database of a single center in Taiwan","volume":"8","author":"Wang","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2025.115224_bib4","first-page":"193","article-title":"Upfront liquid next-generation sequencing in treatment-na\u00efve advanced non-small cell lung cancer patients: a prospective randomised study in the Taiwanese health system","author":"Yang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115224_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115224_bib6","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s12935-021-02382-0","article-title":"The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management","volume":"21","author":"Fernandes","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"19","key":"10.1016\/j.ejca.2025.115224_bib8","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.7150\/thno.34070","article-title":"Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer","volume":"9","author":"Tong","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00016-2019","article-title":"Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions","volume":"5","author":"Hummelink","year":"2019","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115224_bib10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamaoncol.2022.6109","article-title":"Testing for EGFR variants in pleural and pericardial effusion cell-free DNA in patients with non-small cell lung cancer","volume":"9","author":"Lee","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.chest.2023.01.019","article-title":"High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma","volume":"164","author":"Mahmood","year":"2023","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ejca.2025.115224_bib12","first-page":"783","article-title":"cfRNAs as biomarkers in oncology - still experimental or applied tool for personalized medicine already?","volume":"25","author":"Kolenda","year":"2020","journal-title":"Rep Pr Oncol Radio"},{"issue":"3","key":"10.1016\/j.ejca.2025.115224_bib13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1183\/09031936.00043511","article-title":"RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer","volume":"39","author":"Tsai","year":"2012","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.ejca.2025.115224_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/gcc.22647","article-title":"Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion","volume":"57","author":"Wu","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2025.115224_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-024-00736-8","article-title":"Profiling cell-free DNA from malignant pleural effusion for oncogenic driver mutations in patients with treatment-naive stage IV adenocarcinoma: a multicenter prospective study","author":"Chang","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"9","key":"10.1016\/j.ejca.2025.115224_bib16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115224_bib17","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/curroncol29030174","article-title":"Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice","volume":"29","author":"Cho","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2025.115224_bib18","first-page":"10","article-title":"Genomic profiling of driver gene mutations in Chinese patients with non-small cell lung cancer","author":"Meng","year":"2019","journal-title":"Front Genet"},{"issue":"3","key":"10.1016\/j.ejca.2025.115224_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1759-7714.13757","article-title":"Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer","volume":"12","author":"Si","year":"2021","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clon.2019.07.014","article-title":"Differences between the east and the west in managing advanced-stage non-small cell lung cancer","volume":"32","author":"Lee","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115224_bib21","doi-asserted-by":"crossref","first-page":"ix174","DOI":"10.1093\/annonc\/mdz437.044","article-title":"519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia","volume":"30","author":"Kuo","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115224_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/LBR.0000000000000534","article-title":"Yield of malignant pleural effusion for detection of oncogenic driver mutations in lung adenocarcinoma","volume":"26","author":"DeMaio","year":"2019","journal-title":"J Bronchol Inter Pulmonol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115224_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1513\/AnnalsATS.201609-709OC","article-title":"Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma. The effect of preanalytical factors","volume":"14","author":"Carter","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.ejca.2025.115224_bib24","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0000000000000203","article-title":"Multiplexed molecular profiling of lung cancer using pleural effusion","volume":"9","author":"Akamatsu","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115224_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1183\/09031936.00167407","article-title":"Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma","volume":"32","author":"Wu","year":"2008","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ejca.2025.115224_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13402-012-0078-4","article-title":"EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma","volume":"35","author":"Smits","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"10.1016\/j.ejca.2025.115224_bib27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/0300060514539273","article-title":"Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: implication of cancer biological behaviour regulated by EGFR mutation","volume":"42","author":"Zou","year":"2014","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.ejca.2025.115224_bib28","first-page":"147","article-title":"Relationship between EGFR, ALK gene mutation and imaging and pathological features in invasive lung adenocarcinoma","volume":"25","author":"Yang","year":"2022","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12890-024-02886-1","article-title":"Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ejca.2025.115224_bib30","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1038\/srep13574","article-title":"EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway","volume":"5","author":"Tsai","year":"2015","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.ejca.2025.115224_bib31","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-16-2497","article-title":"Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma","volume":"23","author":"Schwaederl\u00e9","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115224_bib32","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/srep06269","article-title":"Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis","volume":"4","author":"Luo","year":"2014","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.ejca.2025.115224_bib33","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2025.115224_bib34","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","article-title":"Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors","volume":"4","author":"Ptashkin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.115224_bib35","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/PO.20.00046","article-title":"Clonal hematopoiesis in late-stage non-small-cell lung cancer and its impact on targeted panel next-generation sequencing","volume":"4","author":"Yaung","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2025.115224_bib36","doi-asserted-by":"crossref","first-page":"e20532-e","DOI":"10.1200\/JCO.2022.40.16_suppl.e20532","article-title":"Clonal hematopoiesis in lung cancer and its impact on liquid biopsy based on targeted deep sequencing","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:45:23Z","timestamp":1777265123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492500005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":36,"alternative-id":["S095980492500005X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115224","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115224"}}